Utility of a single adjusting compartment: A novel methodology for whole body physiologically-based pharmacokinetic modelling

Theoretical Biology and Medical Modelling

Volumn 5, Issue , 2008, Pages

  Ando, Hirotaka ^a   Izawa, Shigeru ^a   Hori, Wataru ^a   Nakagawa, Ippei ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; DICLOFENAC; FLEROXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; IMIPRAMINE; LIDOCAINE; LOMEFLOXACIN; MIDAZOLAM; PAZUFLOXACIN; PHENYTOIN; TOLBUTAMIDE; DRUG; PLASMA PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG HALF LIFE; HALF LIFE TIME; NONHUMAN; PHYSICAL CHEMISTRY; RAT; STEADY STATE; ACTIVE TRANSPORT; ANIMAL; BINDING SITE; BIOLOGICAL MODEL; BLOOD; BODY FLUID COMPARTMENT; COMPARATIVE STUDY; COMPUTER SIMULATION; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; PH; PHARMACOKINETICS; PHYSIOLOGY; PREDICTION AND FORECASTING; TISSUE DISTRIBUTION;

RATTUS;

ANIMALS; BINDING SITES; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD PROTEINS; BODY FLUID COMPARTMENTS; COMPUTER SIMULATION; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PREDICTIVE VALUE OF TESTS; RATS; TISSUE DISTRIBUTION;

EID: 52149095835     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-5-19     Document Type: Article

References (62)

1. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. H Boxenbaum, J Pharmacokinet Biopharm 1982 10 201 227 10.1007/BF01062336 7120049
2. Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection. H Tang M Mayersohn, Drug Metab Dispos 2005 33 1288 1293 10.1124/dmd.105.004127 15919852
3. Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling. MR Shiran NJ Proctor EM Howgate K Rowland-Yeo GT Tucker A Rostami-Hodjegan, Xenobiotica 2006 36 567 580 10.1080/00498250600761662 16864504
4. Modelling and simulation in prediction of human xenobiotic absorption, distribution, metabolism and excretion (ADME): in vitro-in vivo extrapolations (IVIVE). GG Gibson A Rostami-Hodjegan, Xenobiotica 2007 37 1013 1014 10.1080/00498250701649873 17968734
5. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. N Parrott H Jones N Paquereau T Lavé Basic Clin Pharmacol Toxicol 2005 96 193 199 10.1111/j.1742-7843.2005.pto960308.x 15733214
6. MB Reddy, Physiologically Based Pharmacokinetic Modeling: Science And Applications Wiley Interscience: John Wiley & Sons, Inc 2005
7. A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics. HM Jones N Parrott K Jorga T Lavé Clin Pharmacokinet 2006 32 511 542 10.2165/00003088-200645050-00006
8. Prediction of Human Pharmacokinetics Using Physiologically Based Modelling: A Retrospective Analysis of 26 Clinically Tested Drugs. SS De Buck VK Sinha LA Fenu MJ Nijsen CE Mackie RA Gilissen, Drug Metab Dispos 2007 1766 1780 10.1124/dmd.107.015644 17620347
9. Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models. S Björkman, J Pharmacokinet Pharmacodyn 2003 30 285 307 10.1023/A:1026194618660 14650375
10. Mechanistic approaches to volume of distribution predictions: understanding the processes. T Rodgers M Rowland, Pharm Res 2007 24 918 933 10.1007/s11095-006-9210-3 17372687
11. Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats. Y Sawada M Hanano Y Sugiyama T Iga, J Pharmacokinet Biopharm 1985 13 477 492 10.1007/BF01059331 3938813
12. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. K Ito JB Houston, Pharm Res 2005 22 103 112 10.1007/s11095-004-9015-1 15771236
13. Physiologically based pharmacokinetics of drug-drug interaction: a study of tolbutamide-sulfonamide interaction in rats. O Sugita Y Sawada Y Sugiyama T Iga M Hanano, J Pharmacokinet Biopharm 1982 10 297 316 10.1007/BF01059263 7175701
14. Role of the enterohepatic circulation in the elimination of phenytoin in the rat. AM El-hawari GL Plaa, Drug Metab Dispos 1978 6 59 69 23275
15. The european agency for the evaluation of medicinal products veterinary medicines and inspections. Committee for veterinary medicinal products, diclofenac, summary report. EMEA 2003, September: 1-9.
16. Extrapolation of diclofenac clearance from in vitro microsomal metabokism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. S Kumar K Samuel R Subramanian MP Braun RA Stearns SL Chiu DC Evans TA Baillie, J Pharmacol Exp Ther 2002 303 969 978 10.1124/jpet.102.038992 12438516
17. Voltaren®. prescribing information.
18. Central and peripheral tissue distribution of diclofenac after subcutaneous injection in the rat. RF Grace SR Edwards LE Mather Y Lin I Power, Inflammopharmacology 2000 8 43 54 10.1023/B:INFL.0000041131.54496.51
19. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Y Shibata H Takahashi M Chiba Y Ishii, Drug Metab Dispos 2002 30 892 896 10.1124/dmd.30.8.892 12124306
20. Areceptor modulators: in vitro-in vivo correlations. SAG Visser FLC Wolters JM Gubbens-stibbe E Tukker PH Van der graaf LA Peletier M Danhof, J Pharmacol Exp Ther 2003 304 88 101 10.1124/jpet.102.042341 12490579
21. 14C]midazolam in the rat in vitro and in vivo. GK Woo TH Williams SJ Kolis D Warinsky GJ Sasso MA Schwartz, Xenobiotica 1981 11 373 384 7293228
22. Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. S Björkman DR Wada BM Berling G Benoni, J Pharm Sci 2001 90 1226 1241 10.1002/jps.1076 11745776
23. Biliary excretion of diazepam in the rat. T Inaba E Tsutsumi WA Mahon W Kalow, Drug Metab Dispos 1974 2 429 32 4156305
24. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Y Naritomi S Terashita S Kimura A Suzuki A Kagayama Y Sugiyama, Drug Metab Dispos 2001 29 1316 1324 11560875
25. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. P Poulin FP Theil, J Pharm Sci 2002 91 1358 1370 10.1002/jps.10128 11977112
26. Kinetic analysis of phenytoin disposition in rats with experimental renal and hepatic diseases. T Itoh Y Sawada TH Lin T Iga M Hanano, J Pharmacobiodyn 1988 11 289 308 3171873
27. 14C]imipramine in an experimental hepatitis. AM Hackett IC Shaw LA Griffiths, Xenobiotica 1984 14 491 499 6475108
28. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. T Rodgers D Leahy M Rowland, J Pharm Sci 2005 94 1259 1276 10.1002/jps.20322 15858854
29. Drug interactions between imipramine and benzodiazepines in rats. M Okiyama K Ueno S Ohmori T Igarashi H Kitagawa, J Pharm Sci 1988 77 56 63 10.1002/jps.2600770110 2894451
30. Imipramine and desipramine disposition in the elderly. DR Abernethy DJ Greenblatt RI Shader, J Pharmacol Exp Ther 1985 232 183 188 3965690
31. Effect of glycerol-induced acute renal failure on the pharmacokinetics of lidocaine after transdermal application in rats. C Lili N Shibata Y Yoshikawa K Takada, Biol Pharm Bull 2003 26 1150 1154 10.1248/bpb.26.1150 12913267
32. The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. JB Keenaghan RN Boyes, J Pharmacol Exp Ther 1972 180 454 463 5010683
33. Effects of cimetidine on lidocaine distribution in rats. S Shibasaki Y Kawamata F Ueno C Koyama H Itho R Nishigaki K Umemura, J Pharmacobiodyn 1988 11 785 793 3254976
34. Dose-independent pharmacokinetics of intravenous lidocaine in humans. HR Ochs M Knüchel DR Abernethy DJ Greenblatt, J Clin Pharmacol 1983 23 186 188 6863582
35. Clinical pharmacokinetics of epidural and spinal anaesthesia. AG Burm, Clin Pharmacokinet 1989 16 283 311 2663301
36. Kyorin Pharmaceutical Co., Ltd., in house data.
37. Physiologically-based pharmacokinetic analysis of grepafloxacin. Y Nakajima K Hattori M Shinsei N Matsunaga H Iizasa H Sasabe H Akiyama G Miyanmoto E Nakashima, Biol Pharm Bull 2000 23 1077 1083 10993208
38. A Bryskier, Antimicrobial Agents: Antibacterials and Antifungals Washington DC: ASM Press 2005
39. 14C]grepafloxacin in rats. H Akiyama Y Abe N Kusumoto M Odomi, Jpn J Chemotherapy 1995 43 107 124
40. The disposition of gemifloxacin, a new fluoroquinolone antibiotic, in rats and dogs. JV Ramji NE Austin GW Boyle MH Chalker G Duncan AJ Fairless FJ Hollis DF McDonnell TJ Musick PC Shardlow, Drug Metab Dispos 2001 29 435 442 11259328
41. LG Life Sciences. SB-265805. Prescribing Information 2003, April 3.
42. Pharmacokinetics of pazufloxacin mesilate in experimental animals. M Nakata Y Yamashiro M Shimakura M Takahata S Minami Y Watanabe H Narita, Jpn J Chemotherapy 1999 47 65 75
43. 14C] T-3761 in rats and mice. H Hayakawa K Hayashi H Sakai H Ishikura H Takagi Y Nakajima Y Sogame, Jpn J Antibiot 1995 48 671 685 7637202
44. Phase I clinical study of pazufloxacin mesilate. M Nakashima K Uemura K Kosuge T Uematsu, Jpn J Chemotherapy 1999 47 141 175
45. 14C-pazufloxacin mesilate in rats and mice. H Hayakawa Y Takano Y Sogame H Imaizumi Y Nakashima H Narita, Jpn J Chemotherapy 1999 47 88 103
46. 14C]AT-2266 I. single administration. T Fujii H Furukawa K Yoshida H Miyazaki M Hashimoto, Chemotherapy 1984 32 117 135
47. Absorption, distribution, excretion and metabolism of AT-2266 in experimental animals. S Nakamura N Kurobe S Kashimoto T Ohue Y Takase M Shimizu, Chemotherapy 1984 32 86 94
48. Phase I study of AT-2266. M Kawai M Nakanishi N Maekawa, Chemotherapy 1984 32 334 358
49. 14C-fleroxacin in rats and rabbits. Y Nagatsu M Mukai K Takagi H Uchida, Chemotherapy 1990 38 100 114
50. 14C-NY-198 in rats and dogs. O Nagata T Yamada T Yamaguchi E Okezaki, Chemotherapy 1988 36 151 173 10.1159/000138378
51. Phase I study on NY-198. M Nakashima T Uematsu Y Takiguchi A Mizuno, Chemotherapy 1988 36 201 239
52. Physiological parameter values for physiologically based pharmacokinetic models. RP Brown MD Delp SL Lindstedt LR Rhomberg RP Belilies, Toxicology and Industrial Health 1997 13 4 407 484
53. Kinetic evaluation for measurement of in vivo receptor occupancy by psychotropic drug in brain: implication for human studies. K Ito Y Sawada Y Sugiyama M Hanano T Iga, Chem Pharm Bull (Tokyo) 1991 39 1813 1819 1663838
54. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. KW Ward BR Smith, Drug Metab Dispos 2004 32 603 611 10.1124/dmd.32.6.603 15155551
55. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. KW Ward BR Smith, Drug Metab Dispos 2004 32 612 619 10.1124/dmd.32.6.612 15155552
56. Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics. CA Evans LJ Jolivette R Nagilla KW Ward, Drug Metab Dispos 2006 34 1255 1265 10.1124/dmd.105.006619 16621936
57. Numerical Methods with MS Excel. M El-Gebeily B Yushau, TMME 2007 4 84 92
58. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Y Adachi H Suzuki Y Sugiyama, Pharm Res 2001 18 1660 1668 10.1023/A:1013358126640 11785684
59. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. I Tamai J Yamashita Y Kido A Ohnari Y Sai Y Shima K Naruhashi S Koizumi A Tsuji, J Pharmacol Exp Ther 2000 295 146 152 10991972
60. Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. H Sasabe A Tsuji Y Sugiyama, J Pharmacol Exp Ther 1998 284 1033 1039 9495864
61. Application of generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. FA Brightman DE Leahy GE Searle S Thomas, Drug Metab Dispos 2006 34 94 101 10.1124/dmd.105.004838 16221756
62. Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data? GW Caldwell JA Masucci Z Yan W Hageman, Eur J Drug Metab Pharmacokinet 2004 29 133 143 15230342